NCT03198052View on ClinicalTrials.gov

GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 1, 2017

Primary Completion Date

August 1, 2026

Study Completion Date

August 1, 2036

Conditions
Lung CancerCancerImmunotherapyCAR-T Cell
Interventions
BIOLOGICAL

CAR-T cells targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR

CAR-T cells injection: (1-10×10e6/kg CAR-T for each treatment; 3 or more cycles.

Trial Locations (2)

510072

RECRUITING

The First Affiliated Hospital of Sun Yat-sen University, Guangzhou

510260

RECRUITING

The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou

All Listed Sponsors
collaborator

Hunan Zhaotai Yongren Medical Innovation Co. Ltd.

OTHER

collaborator

Guangdong Zhaotai InVivo Biomedicine Co. Ltd.

OTHER

lead

Second Affiliated Hospital of Guangzhou Medical University

OTHER